Complete dosage information for Tirzepatide — threshold, light, common, strong, and heavy dose ranges across 1 route of administration.
Full Tirzepatide profileImportant Safety Notice
Dosage information is for harm reduction purposes only. Individual sensitivity varies greatly. Always start with the lowest effective dose and work your way up slowly. Never eyeball doses — use a milligram scale.
## Overdose Profile There is **no specific antidote** for tirzepatide overdose. Given the 5-day elimination half-life, any overdose effects would be prolonged, requiring extended monitoring and supportive care. ## Expected Overdose Symptoms - **Severe nausea and vomiting** — the most likely acute presentation - **Dehydration** — secondary to GI fluid losses, potentially leading to electrolyte imbalance and acute kidney injury - **Hypoglycemia** — particularly if the patient is concurrently taking insulin or sulfonylureas; less likely with tirzepatide monotherapy due to glucose-dependent mechanism - **Severe abdominal pain** — may indicate drug-induced pancreatitis ## Management - **Supportive care**: IV fluid replacement for dehydration, electrolyte monitoring and correction - **Anti-emetics**: ondansetron (Zofran) for nausea and vomiting - **Glucose monitoring**: frequent blood glucose checks; IV dextrose if hypoglycemia occurs - **Observation**: extended monitoring period (minimum 5-7 days) given the long half-life - **Poison control consultation**: recommended for any suspected overdose - **Dialysis**: unlikely to be effective due to high protein binding (99% albumin-bound)
A common Subcutaneous injection dose of Tirzepatide is 5–10 mg.
The threshold dose for Tirzepatide via Subcutaneous injection is approximately 2.5 mg.
Tirzepatide typically lasts 5–7 days via Subcutaneous injection.
